Registro:

Referencias:

• Fisher, B., Redmond, C., Brown, A., Wolmark, N., Wittliff, J., Fisher, E.R., Treatment of primary breast cancer with chemotherapy and tamoxifen (1981) N Engl J Med, 305, pp. 1-6
• Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy (1992) Lancet, 339, pp. 1-15
• Muss, H.B., Endocrine therapy for advanced breast cancer: A review (1992) Breast Cancer Res Treat, 21, pp. 15-26
• Brunner, N., Clarke, R., Lippman, M.E., Dickson, R.B., Models for studying the progression from hormone-dependency to independency in human breast cancer (1990) Growth Regulation of Cancer, pp. 15-125. , Lippman ME, Dickson RB (eds). New York, Alan Liss
• Ballare, C., Bravo, A.I., Laucella, S., Sorin, I., Cerdeiro, R., Loza, J., Souza Martinez, F., Mordoh, J., DNA synthesis in estrogen receptor-positive human breast cancer takes place preferentially in estrogen receptor-negative cells (1989) Cancer, 64, pp. 842-848
• Robertson, J.F.R., Oestrogen receptor: A stable phenotype in breast cancer (1996) Br J Cancer, 73, pp. 5-12
• Encarnación, C.A., Ciocca, D.R., McGuire, W.L., Clark, G.M., Fuqua, S.A.W., Osborne, C.K., Measurement of steroid hormone receptors in breast cancer patients on tamoxifen (1993) Breast Cancer Res Treat, 26, pp. 237-246
• Pakdel, F., Katzenellenbogen, B.S., Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination (1992) J Biol Chem, 267, pp. 3429-3437
• Mahfoudi, A., Roulet, E., Dauvois, S., Parker, M.G., Wahli, W., Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists (1995) Proc Natl Acad Sci USA, 92, pp. 4206-4210
• Jiang, S., Parker, C.J., Jordan, C.V., A model to describe how a point mutation of the estrogen receptor alters the structure function relationship of antiestrogens (1992) Breast Cancer Res Treat, 26, pp. 139-147
• Castles, C.G., Fuqua, S.A., Klotz, D.M., Hill, S.M., Expression of a constitutively active estrogen receptor variant in the estrogen receptor negative BT-20 human breast cancer cell line (1993) Cancer Res, 53, pp. 5934-5939
• Rea, D., Parker, M.J., Effects of an exon 5 variant of the estrogen receptor in MCF-7 breast cancer cells (1996) Cancer Res, 56, pp. 1556-1563
• Tonetti, D.A., Jordan, V.C., The role of estrogen mutations in tamoxifen-stimulated breast cancer (1997) J Steroid Biochem Molec Biol, 62, pp. 119-128
• Daffada, A.A.I., Johnston, S.R.D., Smith, I.E., Detre, S., King, N., Dowsett, M., Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer (1995) Cancer Res, 55, pp. 288-293
• Karnik, P.S., Kulkarni, S., Liu, X.P., Budd, G.T., Bukowski, R.M., Estrogen receptor mutations in tamoxifen-resistant breast cancer (1994) Cancer Res, 54, pp. 349-353
• Lupu, R., Cardillo, M., Cho, C., Harris, L., Hijazi, M., Perez, C., Rosenberg, K., Tang, C., The significance of heregulin in breast cancer tumor progression and drug resistance (1996) Breast Cancer Res Treat, 38, pp. 57-66
• Reiss, M., Barcellos-Hoff, M.H., Transforming growth factor β in breast cancer: A working hypothesis (1997) Breast Cancer Res Treat, 45, pp. 81-95
• Zhou, D.J., Casey, G., Cline, M.J., Amplification of human int-2 in breast cancers and squamous carcinomas (1988) Oncogene, 2, pp. 279-282
• Clarke, R., Brünner, N., Acquired estrogen independence and antiestrogen resistance in breast cancer. Estrogen receptor-driven phenotypes? (1996) Trends Endocrinol Metab, 7, pp. 291-301
• Edwards, D.P., Weigel, N.L., Nordeen, S.K., Beck, C.A., Modulators of cellular protein phosphorylation after the transactivation function of human progesterone receptor and the biological activity of progesterone antagonists (1993) Breast Cancer Res Treat, 27, pp. 41-56
• Sasano, H., Ozaki, M., Aromatase expression and its localization in human breast cancer (1997) J Steroid Biochem Mol Biol, 61, pp. 293-298
• Osborne, C.K., Fuqua, S.A.W., Mechanism of tamoxifen resistance (1994) Breast Cancer Res Treat, 32, pp. 49-55
• Burger, M.M., Moses, H.L., Mechanisms of growth factor and hormone insensitivity (1997) Int J Cancer, 73, pp. 461-463
• Lanari, C., Molinolo, A.A., Pasqualini, C.D., Induction of mammary adenocarcinomas by modroxyprogesterone aculate in BALB/c mice (1986) Cancer Letters, 33, pp. 215-223
• Molinolo, A.A., Lanari, C., Charreau, E.H., Sanjuan, N., Pasqualini, C.D., Mouse mammary tumors induced by medroxyprogesterone acetate: Immunochemistry and hormonal receptors (1987) J Natl Cancer Inst, 79, pp. 1341-1350
• Kordon, E., Molinolo, A.A., Pasqualini, C.D., Charreau, E.H., Pazos, P., Dran, G., Lanari, C., Progesterone induction of mammary carcinomas in BALB/c female mice. Correlation between hormone dependence and morphology (1993) Breast Cancer Res Treat, 28, pp. 29-39
• Kordon, E., Guerra, F., Molinolo, A.A., Elizalde, P., Charreau, E.H., Pasqualini, C.D., Montecchia, M.F., Lanari, C., Effect of sialoadenectomy on medroxyprogesterone acetate (MPA)-induced mammary carcinogenesis in BALB/c mice (1994) Int J Cancer, 59, pp. 196-203
• Kordon, E., Lanari, C., Molinolo, A.A., Elizalde, P., Charreau, E.H., Pasqualini, C.D., Estrogen inhibition of MPA-induced mouse mammary tumor transplants (1991) Int J Cancer, 49, pp. 900-905
• Satyaswaroop, P.G., Sivarajah, A., Zaino, R.J., Mortel, R., Hormonal control of growth of human endometrial carcinoma in the nude mouse model (1988) Progress in Cancer Res and Therapy, Vol 35. Hormones and Cancer 3, 35, pp. 430-435. , Bresciani F, King RJR, Lippman ME, Raynaud JP (eds). Raven Press, New York
• Gottardis, M.M., Jordan, V.C., Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration (1988) Cancer Res, 48, pp. 5183-5187
• Osborne, K.C., Coronado, C., Allred, K., Wiebe, V., DeGregorio, M., Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of tran-4-hydroxytasmoxifen (1991) J Natl Cancer Inst, 83, pp. 1477-1482
• Darbre, P.D., King, R.J.B., Interaction of different steroid hormones during progression of tumour cells to steroid autonomy (1987) Int J Cancer, 40, pp. 802-806
• Paik, S., Hartmann, D.P., Dickson, R.B., Lippmann, M.E., Antiestrogen resistance in ER positive breast cancer cells (1994) Breast Cancer Res Treat, 31, pp. 301-307
• Alt, F.W., Kellems, R.E., Bertino, J.R., Schimke, R.T., Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured mouse cells (1978) J Biol Chem, 253, pp. 1357-1370
• Markopoulos, C., Berger, U., Wilson, P., Gazet, J.C., Coombes, R.C., Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle (1988) Br J Med, 296, pp. 1349-1351
• Axelrod, D.M., Menendez-Botet, C.J., Kinne, D.W., Osborne, M.P., Levels of estrogen and progesterone receptor proteins in patients with breast cancer during various phases of menses (1988) Cancer Invest, 6, pp. 7-14
• Weimer, D.A., Donegan, W.L., Changes in estrogen and progesterone receptor content of primary breast carcinoma during the menstrual cycle (1987) Breast Cancer Res Treat, 10, pp. 273-278

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------